Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

3.

Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis.

Wei HB, Lu XS, Shang LH, Xu G, Hu J, Che DH, Liu F, Wu Y, Zhang GM, Yu Y.

Arch Med Res. 2011 Jul;42(5):412-20. doi: 10.1016/j.arcmed.2011.07.008. Epub 2011 Aug 7.

PMID:
21827803
4.

No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis.

Yin M, Yan J, Voutsina A, Tibaldi C, Christiani DC, Heist RS, Rosell R, Booton R, Wei Q.

Lung Cancer. 2011 Jun;72(3):370-7. doi: 10.1016/j.lungcan.2010.10.011. Epub 2010 Nov 13.

5.

Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients.

Takenaka T, Yano T, Kiyohara C, Miura N, Kouso H, Ohba T, Kometani T, Shoji F, Yoshino I, Maehara Y.

Lung Cancer. 2010 Jan;67(1):101-7. doi: 10.1016/j.lungcan.2009.03.007.

PMID:
19361884
6.

[Correlation of genetic polymorphisms in nucleotide excision repair system to sensitivity of advanced non-small cell lung cancer patients to platinum-based chemotherapy].

Yuan P, Miao XP, Zhang XM, Wang ZH, Tan W, Zhang XR, Sun Y, Xu BH, Lin DX.

Ai Zheng. 2005 Dec;24(12):1510-3. Chinese.

PMID:
16351803
7.

[Association between polymorphisms of ERCC1 and response in patients with advanced non-small cell lung cancer receiving cisplatin-based chemotherapy].

Wang J, Zhang Q, Zhang H, Wang Q, Yang X, Gu Y, Zhang S.

Zhongguo Fei Ai Za Zhi. 2010 Apr;13(4):337-41. doi: 10.3779/j.issn.1009-3419.2010.04.13. Chinese.

8.
9.

Evaluation of Prediction of Polymorphisms of DNA Repair Genes on the Efficacy of Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer: A Network Meta-Analysis.

Yu SN, Liu GF, Li XF, Fu BH, Dong LX, Zhang SH.

J Cell Biochem. 2017 Dec;118(12):4782-4791. doi: 10.1002/jcb.26147. Epub 2017 Jul 7.

PMID:
28520216
10.

Response to gemcitabine-platinum chemotherapy by single nucleotide polymorphisms of RRM1 and ERCC1 genes in patients with non-small-cell lung cancer.

Oh IJ, Ban HJ, Kim KS, Song SY, Na KJ, Kim YH, Ahn SJ, Choi S, Cho HJ, Kim YC.

Thorac Cancer. 2012 Feb;3(1):19-26. doi: 10.1111/j.1759-7714.2011.00082.x.

PMID:
28920258
12.

Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer--a pilot study.

Krawczyk P, Wojas-Krawczyk K, Mlak R, Kucharczyk T, Biernacka B, Milanowski J.

Folia Histochem Cytobiol. 2012 Apr 24;50(1):80-6. doi: 10.2478/18700.

13.

Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.

Zhao W, Hu L, Xu J, Shen H, Hu Z, Ma H, Shu Y, Shao Y, Yin Y.

Cancer Chemother Pharmacol. 2013 May;71(5):1287-95. doi: 10.1007/s00280-013-2127-8. Epub 2013 Mar 12.

PMID:
23479135
14.

DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.

Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V, Mavroudis D.

Clin Lung Cancer. 2009 Mar;10(2):118-23. doi: 10.3816/CLC.2009.n.015.

PMID:
19362955
15.

A meta-analysis identifies ERCC1 gene polymorphism as a predictor of better patient response to treatment with radiochemotherapy.

Li F, Xie X, Ren X, Zhang J.

Cancer Chemother Pharmacol. 2016 Jun;77(6):1183-91. doi: 10.1007/s00280-016-3015-9. Epub 2016 Apr 21.

PMID:
27100737
16.

[Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].

Qi BL, Li Y, Wang N, Zhou RM, Hu P, Kang S.

Zhonghua Fu Chan Ke Za Zhi. 2013 Nov;48(11):847-52. Chinese.

PMID:
24444563
17.

A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer.

Wei HB, Hu J, Shang LH, Zhang YY, Lu FF, Wei M, Yu Y.

Chin Med J (Engl). 2012 Aug;125(16):2902-7. Review.

PMID:
22932088
18.

Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.

Fleming ND, Agadjanian H, Nassanian H, Miller CW, Orsulic S, Karlan BY, Walsh CS.

Cancer. 2012 Feb 1;118(3):689-97. doi: 10.1002/cncr.26329. Epub 2011 Jul 12. Erratum in: Cancer. 2012 Nov 1;118(21):5450.

19.

Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients.

Pérez-Ramírez C, Cañadas-Garre M, Alnatsha A, Villar E, Delgado JR, Faus-Dáder MJ, Calleja-Hernández MŸ.

Pharmacol Res. 2016 Sep;111:877-884. doi: 10.1016/j.phrs.2016.08.002. Epub 2016 Aug 3.

PMID:
27498158
20.

Polymorphisms in XPD gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients: a meta-analysis of 24 studies.

Qin Q, Zhang C, Yang X, Zhu H, Yang B, Cai J, Cheng H, Ma J, Lu J, Zhan L, Liu J, Liu Z, Xu L, Sun X.

PLoS One. 2013 Nov 15;8(11):e79864. doi: 10.1371/journal.pone.0079864. eCollection 2013.

Supplemental Content

Support Center